We are live on ! Find out more
QNRX

Quoin Pharmaceuticals
QNRX

2 hedge funds and large institutions have $1.45M invested in Quoin Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less capital invested

Capital invested by funds: $2.16M → $1.45M (-$718K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$731K
2
MIFH
Migdal Insurance & Financial Holdings
Israel
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$798K -$731K -1 -50%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$439K – – –
Morgan Stanley
3
Morgan Stanley
New York
$121K – – –
Citigroup
4
Citigroup
New York
$70K – – –
UBS Group
5
UBS Group
Switzerland
$11K – – –
APA
6
American Portfolios Advisors
New York
$7.15K – – –
MIFH
7
Migdal Insurance & Financial Holdings
Israel
– -$10K – –

QNRX Hedge Fund Activity: Q2 2018 in Review

2 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q2 2018, worth a combined $1.45M — down 33% from $2.16M a quarter earlier.

Fund positioning in QNRX was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Sabby Management, cutting an estimated $731K.

  • 2 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $1.45M of Quoin Pharmaceuticals stock for Q2 2018, down 33% quarter-over-quarter.
  • 0 funds opened new Quoin Pharmaceuticals positions in Q2 2018 and 0 closed out.
  • The largest Quoin Pharmaceuticals seller in Q2 2018 was Sabby Management, an estimated $731K sold.

Based on aggregated 13F filings for Q2 2018.